A n antitumor immune response requires both effective presentation of tumor antigen as well as costimulatory signaling of immune effector cells. The ability of tumor cells to escape immune surveillance and recognition may be partially explained by the lack of costimulatory molecule expression by the tumor cells. Thus, attempts to enhance tumor immunogenicity have included transfection of tumor cells with cDNA for the B7.1 costimulatory molecule. Several studies report a decrease in tumorigenicity following transfection of tumors with B7.1 7, 28 , whereas others have described progressive growth of B7.1 ( + ) tumors. 6, 35 These conflicting results may have two explanations. First, there may be differences in the immunogenicity of the tumor model studied 6 and second, the amount of B7.1 expression by the tumor cells may be important. B7.1 must be expressed both at high levels and perhaps on all tumor cells for tumor rejection to occur. 35 To evaluate the effect of B7.1 on tumor immunogenicity, both tumor vaccine and tumor treatment models have been developed. Construction of B7.1 ( + ) tumor vaccines in some models has resulted in protection against subsequent wild -type tumor challenge. 7, 12, 28 Unfortunately, in a clinical model, the presence of a pre -existing tumor burden makes this approach less attractive and a direct treatment model more appealing. B7.1 is one of two known ligands for the CD28 and CTLA -4 receptors on immune effector cells. 2, 5 Whereas binding to CD28 leads to a proliferative T-cell response, CTLA -4 ligation appears down -regulatory. 14, 15, 31 These opposing effects likely act to modulate proliferative responses. The loss of the CTLA -4 receptor in CTLA -4 knockout mice leads to death from overwhelming lymphoproliferation and thus confirms the nature of this receptor. 27, 32 Although CD28 expression is constitutive on resting T cells, preferential binding of CTLA -4 by B7.1 after T-cell activation may occur due to its rapid upregulation and the 10-fold higher affinity of CTLA -4 ( compared to CD28 ) for B7.1. 14 ± 17,21,29,31 In instances where transfection of tumor cells with cDNA for B7.1 results in an antitumor response, CD8 ( + ) T cells appear primarily responsible 28, 35 although a potential role may also exist for natural killer ( NK ) cells. 35 The transfection of cytokine genes into tumor with subsequent tumor placement as a vaccine protects animals from challenge with some wild -type tumors. In particular, IL -12 gene therapy has shown great promise as an effective antitumor agent. When IL -12 gene therapy was applied in the murine model, numerous established tumors regressed. 3, 24, 26 IL -12, in fact, was found superior to other cytokines in promoting tumor regression of established tumor. 23 Gene transfer techniques are now being used in experimental models as an effective means for IL -12 delivery. In contrast to recombinant protein injections, these methods have resulted in decreased toxicity and continued effectiveness regardless of the mode of transfer. 33 The mechanism of IL -12 ±mediated tumor regression is probably multifactoral. The IL -12 protein increases local interferon -( IFN ) levels, 3, 13, 22, 26 leading to a Th 1 -type immune response. 25 The majority of experimental data suggest that CD8 ( + ) T cells are primarily responsible for tumor regression, 4, 25, 26 whereas in one model, both CD4 ( + ) and CD8 ( + ) cells were found to be of equal importance for the antitumor effect. 20 The generation of mice deficient in a defined subpopulation of NK cells also abrogates IL -12± mediated tumor regression. 9, 11 Another mechanism responsible for the antitumor effects of IL -12 is the suppression of tumor angiogenic properties. 30 These properties appear to be mediated by the IFN -inducible protein ( IP-10) , which also increases after addition of IL -12. 1, 18, 26 Although IL -12 has demonstrated antitumor activity in murine models, regression of poorly immunogenic tumors does not occur. 24 IL -12 therapy may fail in these instances because IL -12 ± stimulated effector cells fail to recognize the tumor. Modification of tumor immunogenicity by altering cell surface receptors on tumor cells may make the tumor more susceptible to cytokine therapy. This was observed in a mammary carcinoma model in which transfection of tumor cells with cDNA for B7.1 combined with rIL -12 protein therapy resulted in increased tumor rejection. 8 When B7.1 was utilized as a tumor vaccine with rIL -12 protein adjuvant, prolonged survival was noted in a pulmonary metastases model. Simultaneous cotransfection of B7.1 and IL -12 has demonstrated beneficial results in some tumor models. 22 The mechanism for this complementary effect is not known.
To further define the interaction between B7.1 and IL -12, we hypothesized that B7.1 expression in poorly immunogenic tumors is necessary for IL -12 ± mediated tumor regression. To test this hypothesis, the poorly immunogenic and IL -12 gene therapy± resistant B16 mouse melanoma tumor cells were used. We demonstrate that tumor resistance to IL -12± mediated tumor regression can be eliminated if the tumor is altered to express B7.1.
MATERIALS AND METHODS

Animals
Six -to 8 -week -old female C57 /BL6 mice ( Taconic Farms, Germantown, NY ) were used in this study. Animals were housed and fed standard mouse chow and water ad libitum. All treatments were carried out with strict adherence to animal care and use guidelines.
Cell lines
Wild -type B16 melanoma was maintained in RPMI 1640 medium supplemented with 10% heat -inactivated fetal bovine serum ( Sigma, St. Louis, MO ) , 2 mM L -glutamine, 1 mM sodium pyruvate, 1% Eagle's medium nonessential amino acids ( Biowhittaker, Walkersville, MD ) , and 10 g/ mL ciprofloxacin ( Bayer, West Haven, CT ).
The stable class I (H2D b ) positive B16 cell line (B16 -H2D b ) was a gift from Dr. M. Malkovsky. It was generated by particle -mediated gene transfer ( PMGT ) of the pSRneo vector, containing the Mycobacterium hsp72 gene, into wild -type B16 cells as described previously. 34 Transfectants were cultured and maintained in RPMI medium plus geneticin (G -418; Life Technologies, Grand Island, NY ).
The stable B7.1( + ) / B16 melanoma cell line (B16 ± B7.1) was generated by PMGT of the B7.1 gene into wildtype B16. B7.1( + ) melanoma cells were then selected by FAC sorting and were cultured immediately and maintained in the above medium supplemented with geneticin.
Plasmids
The murine IL -12 expression plasmid pNGVL3 -mIL12 was constructed by insertion of the p35 and p40 IL-12 subunits separated by an internal ribosomal entry site and driven by a single CMV promoter into the pNGVL3 mammalian expression vector (National Gene Vector Laboratory, University of Michigan, Ann Arbor, MI ). Control vectors used in these experiments contained luciferase cDNA, constructed as previously described, 24 or the pNGVL3 plasmid without insert.
Murine tumor model
The abdominal area of the mice was shaved and 1Â10 5 tumor cells in 50 L phosphate -buffered saline were injected intradermally. Tumor growth was monitored every other day and recorded by measuring the diameter in two perpendicular directions using an electronic caliper. Mice were euthanized when the tumor area reached 100 mm 2 .
In vivo gene transfer PMGT was used for gene delivery via a helium -pulsed Powderject VC -1 gene gun ( Powderject Vaccines, Madison, WI ) as previously described. 19 Briefly, plasmid DNA was precipitated onto 2-m gold beads at a density of 2.5 g of DNA per milligram of gold using the spermidine/CaCl 2 method. Particles were suspended in 0.015 mg /mL of polyvinyl pyrrolidine in absolute ethanol. This DNA /gold particle preparation was coated onto the inner surface of Tefzel tubing using a Barnant Mixer (Barrington, IL ). The tubing was cut into 0.5 -in. segments to result in delivery of 0.5 mg gold and 1.25 g plasmid DNA per transfection.
When the tumor diameter reached at least 6 mm 2 ( mean = 10.3 4 mm 2 ) , four transfections were carried out every other day to the skin overlying the tumor. One transfection was directly over the tumor, whereas the other three were performed in a triangular pattern around the tumor. Three treatments were carried out on days 0, 2, and 4.
In vivo IL -12 expression
Tumor-bearing mice were treated with IL-12 cDNA on days 0, 2, and 4 as described previously. Tumor harvested on days 5, 6, and 7 was homogenized. The amount of IL -12 protein was determined by enzyme -linked immunoassay. To confirm that the IL -12 was functional, a portion of homogenized tumor was evaluated for IFN expression.
Spleen and lymph nodes
Prior to and during IL -12 treatment of established B7.1 ( + ) and B7.1( À ) B16 tumors, two mice from each group were euthanized on days 0, 3, and 7. Axillary lymph nodes were immediately harvested and minced through a 70-m nylon cell strainer ( Becton Dickinson, Franklin Lakes, NJ ). Red blood cells were lysed using ACK lysing buffer ( Biowhittaker ) and remaining cells counted via cytometer. Cells were then stained appropriately for four-color flow cytometry as described below.
For coculture experiments, spleens were harvested and prepared as above. Flow cytometry was performed both immediately and after 7 -day coculture with wild -type [ B7.1 ( À ) ] B16. Cocultures were performed in 24-well plates at 378C and 5% CO 2 and consisted of 4Â10 6 effectors /mL and 0.5Â10 5 stimulators /mL ( wild -type B16 irradiated at 10,000 rad ) plus 2 L 50 mM 2-mercaptoethanol (Sigma) in 2 mL volumes / well. After 7 days, splenocytes were harvested, counted, and suspended as necessary for flow cytometry. Four-color flow cytometry was performed using a FACSCalibur ( Becton Dickinson ) equipped with an aircooled 488 -nm argon ion laser and 635-nm red diode. Again, 0.5Â10 6 splenocytes were incubated with PE ±anti -CD28, PE ±anti -CTLA -4, FITC ± pan-NK, FITC± anti -CD4, or APC ± anti -CD8 antibodies (Pharmingen ) along with respective isotype controls antibodies on ice for 30 minutes. Cells were then washed and resuspended as above. Cytometric analysis was performed using the CellQuest analysis program ( Becton Dickinson ).
Statistical analysis
Tumor data. The instantaneous rate of tumor growth was estimated for each mouse. This was estimated as the regression slope of natural log tumor size with time (days ) . The rates of tumor growth were compared between the groups with analysis of variance ( ANOVA ). Pair-wise comparisons of the treatment groups were performed with Fisher's least significant difference procedure. The rates at which tumors reached a size of 100 mm 2 were estimated with Kaplan -Meier graphs. These rates were compared between groups with the log -rank test. All analyses were performed with SAS statistical software ( SAS Institute, Cary, NC ). Flow cytometry data. Differences between the groups were tested for with ANOVA. Pair-wise comparisons of the treatment groups were performed with Fisher's least significant difference procedure. All analyses were performed with SAS statistical software (SAS Institute ).
RESULTS
Cell surface gene expression
High levels of B7.1 expression by the B16 ± B7.1 cell line were demonstrated by flow cytometry using FITC -labeled anti -CD80 antibodies. In contrast, no B7.1 expression could be detected on either the wild -type B16 melanoma or the B16 -H2D b cell line ( Fig 1A ) . Only minimal H2D b surface expression was detected on the wild -type B16 tumor (Fig 1B ) . In contrast, a pronounced shift was noted for the B16 -H2D b cell. A slight shift for the MHC class I staining was also seen for the B16 ± B7.1 cell line, although this was not as pronounced as for B16 -H2D b . No MHC class II (IA b ) expression was detected on any of the cell lines used ( data not shown) .
IL -12 gene expression
In vivo production of IL -12 at the tumor site was confirmed by enzyme -linked immunoassay of tissue homogenates. IL-12 protein was detected at the tumor site for both wild -type (Fig 2A ) .
The amount of IFN in tumor homogenates was determined to evaluate the biologic activity of IL -12 in the tumor microenvironment. IFN levels were higher in IL -12 cDNA ± treated wild -type B16 and in B16 ±B7.1 compared to tumors prior to IL -12 cDNA treatment (Fig 2B) .
Tumor cell expression of B7.1 eliminates resistance to IL -12 therapy
Wild -type B16 and 100% B7.1( + ) (B16 ± B7.1 ) were mixed in appropriate ratios to obtain a tumor inoculum expressing B7.1 in 50% and 80% of cells. These cells were then used for intradermal injection and the resulting tumors tracked with luciferase or IL -12 cDNA.
Although the 100% B7.1 ( + ) ( B16 ±B7.1) tumors demonstrated a slight delay in initial growth, there were no significant differences in tumor size between groups at the beginning of IL -12 treatment ( P= .81) . No differences in growth rates were apparent between the other groups prior to IL -12 treatment.
Upon completion of three treatments, tumor growth continued in both the B16 ±B7 50% wild -type group ( treated with IL-12) as well as in the 100% B16 ±B7 control group ( treated with luciferase) . In contrast, growth rates were slowed in the 80% B16 ± B.7 IL -12 ± treated group (P=.001 ) compared to the luciferase control group. The 100% B16 ± B7 IL-12± treated group had immediate regression of their established tumors in all instances ( P= .001 ) ( Fig 3 ) . None of the mice in the control group ( 100% B16 ±B7 / luciferase) or the 50% B16 ±B7 / IL-12 Cellular composition of splenocytes ( percent positive cells ) in animals that rejected B16 ± B7 after IL -12 cDNA treatment and rejected wild -type B16 after rechallenge ( B -R ) , that rejected B16 ± B7 tumor after IL -12 cDNA treatment and developed wild -type B16 tumor after rechallenge ( B -P ) , or that rejected B16 ± H2D b after IL -12 cDNA treatment and rejected wild -type B16 ( I -R ) . Populations are presented before and after coculture with irradiated wild -type B16. group survived past day 40. In contrast, 100% of the mice in the 100% B16 ± B7 /IL -12 treatment group was alive at day 50 without evidence of tumor. A 67% survival rate was noted in the 80% B16 ± B7 /IL -12 group ( P= .004 ), whereas 30% of mice with tumors expressing class I alone (B16 -H2D b ) was alive 50 days after IL -12 therapy ( P= .12) (Fig 4 ) .
The 
B7.1 receptor changes induced by IL -12
Treatment -related changes in CD28 and CTLA -4 receptor expression were measured in splenocytes harvested from: ( a) two mice that rejected B16 ± B7 tumor after IL-12 cDNA treatment and developed wild -type B16 tumor after rechallenge; (b ) two mice that rejected B16 ± B7 after IL-12 cDNA treatment and rejected wild -type B16 after rechallenge; and (c ) two mice that rejected B16 -H2D b after IL-12 cDNA treatment and rejected wild -type B16. Splenocytes were evaluated by flow cytometry immediately and after a 7 -day coculture with irradiated wild -type B16 tumor cells ( Table 1) . Prior to coculture, there were no significant differences in CD28 or CTLA -4 expression on CD8 + or NK cells between groups 1 and 2. After a 7 -day coculture, a significant increase in the percentage of CD8 + cells was seen in the group rejecting tumor compared to those that did not ( P= .01 ). The NK population also increased, although these changes were not significantly different between groups ( P= .08 ) ( Table 1 ). CD28 expression increased after coculture in CD8 + cells from the B16 ± B7 group rejecting tumor, whereas a decrease was seen in those unable to reject tumor ( P <.001 ) (Fig 5A and B ). An increase in CD28 expression was seen on the NK populations, although these changes occurred in both groups with no significant differences between them ( P= .81 ) ( Fig 5C and D ) . A pronounced difference in CTLA -4 expression was noted in NK populations ( P= .01) ( Fig 5C and D ) . This change was due to the large increase after cocultures in CTLA -4 expression of NK cells observed in mice unable to reject tumor rechallenge. In contrast, a small but significant increase in CTLA -4 expression was seen on CD8 + cells from mice rejecting tumor challenge compared to those that did not (P=.04 ) (Fig 5A and B ) .
The B16 -H2D b group (group 3 ) demonstrated a 5 -fold increase in CD8 cell CD28 expression after coculture with wild -type B16 ( P= .001 ) (Fig 5A and B ) , an increase which was not seen in the B16 ± B7 group that rejected tumor. In these mice, however, evaluation of the NK population revealed only a small increase in CD28 expression after coculture, whereas CTLA -4 expression ( which initially was higher than the other groups ) did not change significantly (Fig 5C and D ) .
B7.1 ( + ) and B7.1 ( À ) IL -12 treatment groups demonstrated CD28 / CTLA -4 effector cell changes
In a second experiment, particle -mediated IL -12 or control gene therapy was again performed (days 0, 2, and 4 ) on established B16 ± B7 tumors or wild -type B16 tumor controls. To investigate acute changes that may account for the antitumor effects of B7.1 in combination with IL -12, two mice from each group were euthanized on days 0, 3, and 7 during IL -12 treatment after which regional lymph nodes were harvested. CD28 expression on NK and CD8 + T cells from regional lymph nodes was found to peak at day 3 for both B16 ± B7 and wild -type B16 treatment groups (Fig 6) . At day 3, greater CD28 expression was observed on CD8 + cells in the wild -type B16 compared to the B16 ±B7 treatment group ( P=.002) . Similar changes were also observed on cells taken from the spleens of these animals, with peak CD28 expression again occurring on day 3 for both cell types in the B16 group and on CD8 + cells of the B16 ± B7 group ( data not shown ).
Only low levels of CTLA -4 expression could be detected on the CD8 + T-cell population and did not change during treatment. There was significantly more CTLA -4 expression in regional lymph nodes at the start of treatment in the B16 group compared to the B16 ±B7 group ( P= .03) . This increased expression in mice with established B16 tumors remained elevated throughout IL -12 treatment (Fig 6) .
DISCUSSION
The costimulatory molecule B7.1 has been shown to enhance as well as suppress immunogenicity, depending on the tumor model. 6, 35 Even in identical animals implanted in vivo with the murine melanoma cell line B16 modified to express B7.1, the tumor may be rejected or found to grow. 28, 35 Our results agree with the latter findings as growth of B16 transfected with B7.1 was delayed slightly but continued in all cases. Despite the ability of this B7.1-transfected tumor to maintain its tumorigenicity, B7.1 expression allowed for IL -12 ±mediated regression.
The requirement for B7.1 expression in tumor cells for effective IL -12 gene therapy may explain the disparate data on the effectiveness of IL -12 gene therapy in different model systems. IL -12 gene therapy alone resulted in regression of B7.1( + ) established subcutaneous and hepatic wild -type murine CT26. 33 That B7.1 is necessary for IL -12 ± mediated regression is confirmed in this report by the lack of tumor regression in parental [ B7.1 ( À ) ] B16 and complete regression in B7.1 -transfected B16.
However, all tumor cells must express B7.1 for optimal antitumor efficacy. This suggests that effector cell targeting, and not the proliferate effector cell response, is necessary for tumor killing. This conclusion is supported by in vitro studies which demonstrate that IL -12 ± activated NK cells failed to recognize B7.1 ( + ) tumor cells in the presence of B7.1 blocking antibodies. 10 The necessity for high levels of B7.1 expression in this system is problematic. The majority of poorly immunogenic murine tumors ( which presumably most closely resemble human tumors ) are B7.1 ( À ). IL -12 then may not effectively eradicate human tumors that do not consistently express B7.1 in the majority of tumor cells.
The B7.1 cell surface costimulatory molecule in transfected B16 cells interacts with effector cells via the CD28 and CTLA -4 receptors. Our data suggest that B7.1 expression, and subsequent ligation of one or both of these receptors, is essential for recognition and killing of tumors by stimulated T and NK cells. The expression of class I offers some enhancement of tumor killing, but is not as effective as B7.1. B7.1 tumor expression alone is not sufficient for tumor regression to occur. IL -12 thus plays a critical role in the B7.1/ CD28 / CTLA -4 interaction that is not completely understood. IL-12 may activate a tumor-specific immune response by alteration of the CD28:CTLA -4 ratio on immune effector cells. This is supported by in vitro data that confirm the addition of IL -12 ±induced greater proliferation and cytokine production of human T-cells than B7.1/ CD28 interaction alone. 10 The expression of B7.1 on the tumor cell surface after treatment of the initial tumor had no effect on the percentage of CD8 cells in regional nodes. NK cell CTLA -4 expression was significantly higher and remained greater during treatment with IL -12 cDNA in B7.1 ( À ) when compared to B7.1( + ) tumors. CD28 expression increased during treatment in both T and NK cells. The increase in CD28 expression was not dependent on B7.1 expression and in fact was greater in IL -12 ± cDNA ±treated B7.1 ( À ) tumors. The enhanced CTLA -4 expression on regional effector cells suggests that B7.1 ( + ) tumors may prevent up-regulation of the inhibitory CTLA -4 receptor. The acute effect on tumor treated with IL-12 cDNA led to tumor regression in all cases. This effect is interesting, but effective clinical antitumor efficacy will require eradication of micrometastatic disease distant from the primary tumor.
Fifty percent of animals with tumor regression was protected from rechallenge with wild -type B16. B7.1 expression is therefore not always necessary for tumor rejection when the animal has previously rejected a B7.1( + ) tumor. In order to examine the development of a memory response to the parental B7.1 ( À ) tumor after eradication of the tumor, animals that rejected wild -type tumor rechallenge ( i.e., those that developed a memory immune response) were compared to animals that were unable to reject wildtype tumor rechallenge ( i.e., animals that did not develop a memory response ). CD8 ( + ) T cells were more prevalent in the spleens of those animals that rejected wild -type tumor. These CD8 ( + ) cells had an increase in expression of CD28 on their cell surface. No differences in CD28 between groups were noted on NK cells. CTLA -4 was greatly increased in the spleens of those animals that developed tumor after rechallenge. This effect was not noted in CD8 ( + ) cells. The increase in number of CD8 ( + ) T cells in the spleens of mice that rejected tumor rechallenge compared to mice that did not suggests that CD8 T cells are important for IL -12 ±mediated rejection of B7.1 ( + ) tumors. The up -regulation of CTLA -4 in animals that either had primary tumors, which were unresponsive to IL -12 cDNA therapy, or did not reject rechallenge with wild -type tumors suggests that CTLA -4 up -regulation is a critical event in resistance to tumor rejection induced by IL -12 cDNA treatment.
In summary, the expression of B7.1 on the poorly immunogenic B16 murine melanoma is necessary for IL -12 ±mediated tumor regression. Animals that reject the B7.1( + ) tumor also reject treatment with wild -type tumor in 50% of cases. B7.1 expression is necessary in the vast majority of tumor cells for this IL -12 ±mediated effect to occur.
